ClinicalTrials.gg
Not yet recruitingNCT07562724DEMO-OBUpdated May 14, 2026

Diet and WB-EMS Effects in Obesity

An interventional study of Energy-Restricted Diet and Whole-Body Electromyostimulation (WB-EMS) in Obesity & Overweight, Metabolic Disorders and Electrotherapy, sponsored by Firat University. Not yet recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Firat University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.

Planned enrollment
141st of 192
40 · median 64
Started
2026
with 59 others
No phase
161 of 353
29 open now
Primary completion
2027-01
later than 51 of 89 live
Registered
278th of 353
by date

Among the 353 studies in Obesity with a site in Turkey, this one is the 141st largest by planned enrollment of the 192 interventional ones that give a count, is one of 60 that started in 2026, is one of 161 with no phase, reaches primary completion later than 51 of the 89 other live ones, and was the 278th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Obesity with a site in Turkey, or all of them as a file.
02

Study summary

Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness.

Whole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood.

This randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks.

Primary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.

03

Conditions studied

  • Obesity & Overweight
  • Metabolic Disorders
  • Electrotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • (BMI) ≥ 30 kg/m²
  • Sedentary lifestyle (less than 2 hours of structured exercise per week)
  • Willingness to participate and provide written

Exclusion criteria

Exclusion Criteria:

  • Presence of pacemaker or implantable cardioverter-defibrillator
  • Known cardiovascular disease or severe chronic illness
  • Pregnancy or breastfeeding
  • Uncontrolled diabetes or severe metabolic disorders
  • Active or cancer treatment
  • Severe renal or hepatic failure
  • Acute infection or inflammatory disease
  • Orthopedic conditions limiting physical activity
  • Use of medications affecting body composition or appetite (e.g., , weight-loss drugs)
  • Regular resistance training within the last 3 months
  • Substance abuse, including alcohol or drug dependency
  • Psychiatric or cognitive conditions affecting adherence to the study protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Diet Only

    Participants receive an individualized energy-restricted diet program.

    Behavioral: Energy-Restricted Diet

  • Experimental
    Diet + WB-EMS

    Participants receive an energy-restricted diet combined with whole-body electromyostimulation (WB-EMS).

    Behavioral: Energy-Restricted Diet · Device: Whole-Body Electromyostimulation (WB-EMS)

Interventions

  • BehavioralEnergy-Restricted Diet

    A personalized diet with approximately 750 kcal/day energy deficit.

  • DeviceWhole-Body Electromyostimulation (WB-EMS)

    Whole-body electromyostimulation applied 2-3 times per week for 8 weeks under supervision.

06

What researchers measure

Primary outcomes

  1. Change in serum irisin levels

    Assessment of change in circulating irisin levels measured by ELISA.

    Time frame: Baseline to 8 weeks

Secondary outcomes

  1. Change in serum myostatin levels

    Assessment of change in circulating myostatin levels measured by ELISA.

    Time frame: Baseline to 8 weeks

  2. Change in serum leptin levels

    Assessment of change in circulating leptin levels.

    Time frame: Baseline to 8 weeks

  3. Change in serum adiponectin levels

    Assessment of change in circulating adiponectin levels.

    Time frame: Baseline to 8 weeks

  4. Change in serum FGF-21 levels

    Assessment of change in circulating fibroblast growth factor-21 levels.

    Time frame: Baseline to 8 weeks

  5. Change in serum ghrelin levels

    Assessment of change in circulating ghrelin levels.

    Time frame: Baseline to 8 weeks

  6. Change in serum GLP-1 levels

    Assessment of change in circulating GLP-1 levels.

    Time frame: Baseline to 8 weeks

  7. Change in fat mass

    Assessment of change in total body fat mass measured by bioelectrical impedance analysis (BIA).

    Time frame: Baseline to 8 weeks

  8. Change in fat-free mass

    Assessment of change in fat-free mass measured by bioelectrical impedance analysis (BIA).

    Time frame: Baseline to 8 weeks

  9. Change in body fat percentage

    Assessment of change in body fat percentage measured by bioelectrical impedance analysis (BIA).

    Time frame: Baseline to 8 weeks

  10. Change in eating behavior scores

    Assessment of eating behavior using the Three-Factor Eating Questionnaire-Revised 21 (TFEQ-R21). The questionnaire evaluates cognitive restraint, uncontrolled eating, and emotional eating behaviors. Scores range from 21 to 84, with higher scores indicating more problematic eating behaviors.

    Time frame: Baseline to 8 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy, ethical, and data protection considerations. The dataset contains sensitive clinical and biochemical information, and sharing is restricted to ensure participant confidentiality in accordance with institutional policies and applicable regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 1, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jan 20, 2027
CompletionEst.
Jun 20, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07562724
Lead sponsor
Firat University
Responsible party
Murat Açık (Assistant Professor, PhD, Firat University) — Principal investigator
First posted
May 1, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jan 20, 2027 (estimated)
Completion
Jun 20, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Murat Acik, PhD
Contact
macik@firat.edu.tr
+90 544 111 81 24
Muharrem Gökhan Beydağı, PhD
Contact
mgbeydagi@firat.edu.tr
+905323581105

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion